VIENNA--(BUSINESS WIRE)--OncoOne, a biotechnology company utilizing its expert knowledge in antibody engineering to support the further growth of targeted radiopharmaceutical therapies globally, announced their new Scientific Advisory Board (SAB) members whose collective expertise spans foundational research, translational medicine and scientific collaborations. The interdisciplinary guidance from the SAB will be instrumental in advancing and broadening the company’s PreTarg-it®, a modular plat
OncoOne Establishes Scientific Advisory Board to Support its Modular PreTarg-it® Platform for Radionuclide Therapies
